Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome

Digestive and Liver Disease

Volumn 44, Issue 5, 2012, Pages 419-425

  Fattovich, Giovanna ^a,b   Svegliati Baroni, Gianluca ^c   Pasino, Michela ^a,b   Pierantonelli, Irene ^c   Covolo, Loredana ^d   Ieluzzi, Donatella ^b,e   Passigato, Nicola ^b   Tonon, Angelo ^b   Faraci, Maria Grazia ^c   Guido, Maria ^f   Negro, Francesco ^g  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e UNIVERSITY OF VERONA   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antiviral therapy; Chronic hepatitis; Hepatitis C virus; Homeostasis model assessment of insulin resistance (HOMA IR); Oral glucose sensitivity (OGIS) index

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; FATTY LIVER; FEMALE; FERRITIN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HOMEOSTASIS; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBSERVATIONAL STUDY; ORAL GLUCOSE TOLERANCE TEST; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; THROMBOCYTE COUNT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ANTIVIRAL AGENTS; BLOOD GLUCOSE; FEMALE; FERRITINS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; RNA;

EID: 84859209957     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2011.12.006     Document Type: Article

References (36)

1. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567.
2. Missiha S.B., Ostrowski M., Heathcote E.J. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008, 134:1699-1714.
3. Ghany M.G., Strader D.B., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
4. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who respond less well?. Ann Intern Med 2004, 140:370-381.
5. Bressler B.L., Guindi M., Tomlinson G., et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003, 38:639-644.
6. O'Brien T.R., Interferon-alfa interferon-λ and hepatitis C. Nat Genet 2009, 41:1048-1050.
7. Harrison S.A. Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment. Clin Gastroenterol Hepatol 2008, 6:864-876.
8. Romero-Gómez M., Del Mar Viloria M., Andrade R.J., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005, 128:636-641.
9. D'Souza R., Sabin C.A., Foster G.R. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005, 100:1509-1515.
10. Poustchi H., Negro F., Hui J., et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008, 48:28-34.
11. Moucari R., Ripault M.P., Martinot-Peignoux M., et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009, 58:1662-1669.
12. Dai C.Y., Huang J.F., Hsieh M.Y., et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009, 50:712-718.
13. Mizuta T., Kawaguchi Y., Eguchi Y., et al. Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load. Dig Dis Sci 2010, 55:183-189.
14. Khattab M., Eslam M., Sharwae M.A., et al. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010, 105:1970-1977.
15. Petta S., Cammà C., Di Marco V., et al. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. Antivir Ther 2009, 14:631-639.
16. Angelico F., Francioso S., Del Ben M., et al. Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients. Aliment Pharmacol Ther 2009, 30:444-451.
17. Akuta N., Suzuki F., Hirakawa M., et al. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J Med Virol 2009, 81:1032-1039.
18. Fattovich G., Covolo L., Pasino M., et al. The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. Liver Int 2010, 31:66-74.
19. Fattovich G., Covolo L., Bibert S., et al. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 2011, 33:1162-1172.
20. Lam K.D., Bacchetti P., Abbasi F., et al. Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: impact of obesity and ethnicity. Hepatology 2010, 52:38-46.
21. Stumvall M., Mitrakou A., Pimenta W., et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000, 23:295-301.
22. Mari A., Pacini G., Murphy E., et al. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001, 24:539-548.
23. Expert panel on detection evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
24. Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003, 21:1011-1053.
25. Bonora E., Targher G., Alberiche M., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degree of glucose tolerance and insulin sensitivity. Diabetes care 2000, 23:57-63.
26. Svegliati-Baroni G., Bugianesi E., Bouserhal T., et al. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. Gut 2007, 56:1296-1301.
27. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996, 24:289-293.
28. Brunt E.M., Janney C.G., Di Bisceglie A.M., et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
29. Shintani Y., Fujie H., Miyoshi H., et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004, 126:840-848.
30. Pazienza V., Clèment S., Pugnale P., et al. The hepatitis C virus core protein of genotype 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007, 45:1164-1171.
31. Honda M., Sakai A., Yamashita T., et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010, 139:499-509.
32. Durante-Mangoni E., Zampino R., Portella G., et al. Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment. Clin Infect Dis 2009, 15:498-506.
33. Grasso A., Malfatti F., De Leo P., et al. Insulin resistance predicts rapid virologic response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2009, 51:984-990.
34. Deltenre P., Louvet A., Lemoine M., et al. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol 2011, 55:1187-1194.
35. Ferrarini E., Mari A. How to measure insulin sensitivity. J Hypertens 1998, 16:895-906.
36. Conjeevaram H.S., Wahed A.S., Afdhal N., et al. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology 2011, 140:469-477.